The article discusses five trends in Real-World Evidence (RWE) that are expected to reshape drug development, regulation, and market access in 2025-2026. These trends include increased use of RWE in regulatory submissions, expanded use of RWE in market access decisions, and the integration of RWE into clinical trials. The author, Massoud Toussi, highlights the potential benefits and challenges of these trends.